Trial Profile
A Study Evaluated the Efficacy of Vemurafenib in Patients with BRAF Mutated Malignant Melanoma Who Failed Trametinib Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Dec 2015
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 08 Dec 2015 New trial record